Found 6 Melanoma trials
A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
PET/CT imaging as a measure of response in patients with advanced melanoma on immunotherapy plus hydroxychloroquine.
The research study is a companion trial to the LIMIT Melanoma Trial, This study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on participants with advanced melanoma who are participating in the LIMIT Melanoma Trial. The imaging agent could …
UPCC 09618: Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Phase 2
The main purpose of this study is to determine the rate of positive sentinel lymph nodes (i.e. the closest draining lymph node(s) to the primary melanoma site) and to test whether treatment with pembrolizumab before surgery to remove melanoma reduces the rate of positive sentinel lymph nodes in patients with …
A Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma
A Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma
KEYMAKER-U02- substudy 02B
Phase 1
Patients from Penn Medicine's Abramson Cancer Center will be approached for participation.This sub-study is part of a larger research study that is testing experimental treatments for melanoma. Various study drugs will be tested in combination with pembrolizumab in this study. Treatment groups include: a) MK-7684 and pembrolizumab b) pembrolizumab alone …
UPCC 03623: A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Phase 2
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
